Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2012-04-23 Capital/Financing Update
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Allied closes Rights Issue Capital Raising 2 pages 276.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Allied Closes Rights Issue Capital Raising' and details the completion of a rights issue raising $1.9M, with plans to raise a total of $4.3M. It discusses the use of funds, shareholder support, and mentions placement and rights issue activities. There are no financial statements or detailed financial performance data, nor is it a report or transcript. The content focuses on capital raising and financing activities. The document length is 4178 characters, which is relatively short but contains substantive information about financing, not just a notice or report publication announcement. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2012-04-23 English
Allied announces Coridon license to vector technology 3 pages 278.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement from Allied Healthcare Group providing an update on Coridon's licensing of vector technology and progress towards a Phase I study. It discusses agreements, manufacturing contracts, and technology details but does not contain financial statements, detailed financial analysis, or regulatory filings. The content is an operational update and progress announcement rather than a financial report or regulatory filing. It is not a full annual or interim report, earnings release, or management discussion. The document is longer than 5,000 characters and provides substantive information about business progress and partnerships, which fits best under Capital/Financing Update (CAP) as it relates to licensing and manufacturing agreements supporting clinical development, which are capital and financing related activities. Therefore, the most appropriate classification is CAP with high confidence.
2012-04-16 English
Positive Phase II follow up data from CardioCel 2 pages 182.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Allied Healthcare Group dated April 5, 2012, reporting positive 2 and 3 year follow-up clinical trial data for their CardioCel product. It focuses on clinical trial results and product information rather than financial data, regulatory filings, or management changes. The document is about clinical trial follow-up data and does not contain financial statements, earnings, or governance information. It is a corporate announcement about clinical trial progress and product development, not a financial or regulatory report. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2012-04-04 English
Change to Allied Board and Appendix 3Z 3 pages 529.4KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated April 3, 2012, regarding the resignation of a director, Mr. Robert Towner, from Allied Healthcare Group Limited. It includes details about the director's resignation, thanks for his service, and mentions the completion of a merger. Additionally, it contains an Appendix 3Z Final Director's Interest Notice, which is a regulatory form disclosing the director's securities holdings and interests as required by ASX listing rules. The content focuses on a change in the company's board of directors and the disclosure of the director's shareholdings. There are no financial statements, earnings data, or detailed management discussion. The primary purpose is to announce a board change and disclose director interests, fitting the category of Board/Management Information (MANG). The document length is 4736 characters, which is sufficient for a full announcement rather than a brief notice. Therefore, the correct classification is MANG with high confidence.
2012-04-02 English
Allied announces successful implant of GyneCel 2 pages 270.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Allied Healthcare Group about the successful implantation of a medical product (ADAPT-treated patch) in clinical trials. It discusses clinical trial progress, product applications, and future expectations for data release. There is no financial data, regulatory filing, or report attached or referenced as being published. The content is a corporate announcement about product development and clinical trial results, not a financial report, management change, or shareholder meeting material. Therefore, it fits best as a general regulatory announcement about company progress and product development, which falls under Regulatory Filings (RNS).
2012-03-28 English
Top 20 Shareholders and Change to Significant Shareholders 10 pages 2.6MB
Regulatory Filings
2012-03-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.